IP Library Granted Patent US 11,602,508
Granted Patent B2
US 11,602,508 · App. 17/872,450 · Granted Mar 14, 2023

Norepinephrine compositions and methods therefor

Inventors: Tushar Hingorani (Bridgewater, NJ); Kumaresh Soppimath (Skillman, NJ)
Assignee: NEVAKAR INJECTABLES INC.
A61K31/137A61K9/0019A61K47/12A61K47/183A61P9/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,602,508
App. No.
17/872,450
Granted
Mar 14, 2023
Kind
B2
Abstract

The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.

Claims (16)

1. A ready-to-administer norepinephrine composition, comprising:

an aqueous solution having a pH range of between 3.7 and 4.3, wherein the aqueous solution comprises:

norepinephrine present at a concentration of between 10 μg/ml and 100 μg/ml, wherein the norepinephrine initially comprises at least 95% of R-isomer as determined by HPLC;

a chelating agent comprising a tartrate bicarboxylic acid, wherein the chelating agent is present at a concentration of between 10 μg/ml and 100 μg/ml; and

a tonicity agent,

wherein the ready-to-administer norepinephrine composition is substantially free of antioxidants; and

wherein after storage at 25±2° C. and 60±5% relative humidity over at least three months, the norepinephrine comprises at least 90% R-isomer as determined by HPLC.

2. The composition of claim 1 , wherein the tonicity agent is present in an amount to obtain osmolality of the solution of between 260 mOsm/kg and 340 mOsm/kg.

3. The composition of claim 1 , wherein the tonicity agent comprises a pharmaceutically acceptable salt and is present in an amount of between 0.6 wt % and 1.2 wt %.

4. The composition of claim 1 , wherein the tonicity agent comprises dextrose.

5. The composition of claim 1 , wherein the tonicity agent comprises NaCl.

6. The composition of claim 1 , wherein the composition is sterile.

7. The composition of claim 1 , wherein the norepinephrine comprises one or more of norepinephrine acid, norepinephrine mineral salt and norepinephrine organic salt.

8. The composition of claim 1 , wherein the norepinephrine comprises a norepinephrine organic salt.

9. The composition of claim 1 , wherein the composition is free of added buffer.

10. The composition of claim 1 , wherein the chelating agent further comprises an aminopolycarboxylic acid.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2026
From: NEVAKAR INJECTABLES INC.
To: NEVAKAR PHARMACEUTICALS, INC.
Reel/Frame 074672/0415 →
SECURITY INTEREST Recorded May 9, 2023
From: OXFORD FINANCE LLC
To: NOVAQUEST CO-INVESTMENT FUND X, L.P.
Reel/Frame 063588/0122 →
SECURITY INTEREST Recorded May 9, 2023
From: NEVAKAR INJECTABLES INC.
To: NOVAQUEST CO-INVESTMENT FUND IX, L.P.
Reel/Frame 063583/0948 →
PATENT SECURITY AGREEMENT Recorded May 4, 2023
From: NEVAKAR INJECTABLES INC.
To: H.I.G. BIO - NEVAKAR, L.P.
Reel/Frame 063545/0646 →
SECURITY INTEREST Recorded Jan 18, 2023
From: NEVAKAR INJECTABLES INC
To: OXFORD FINANCE LLC
Reel/Frame 062405/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2022
From: PURI, NAVNEET; SOPPIMATH, KUMARESH; AKASAPU, PREM SAGAR; YADAV, VIVEK; ILITCHEV, IOURI V.; GARAPATI, SRIRAMYA; HINGORANI, TUSHAR
To: NEVAKAR LLC
Reel/Frame 060606/0982 →
CHANGE OF NAME Recorded Jul 25, 2022
From: NEVAKAR LLC
To: NEVAKAR INC.
Reel/Frame 060879/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2022
From: NEVAKAR INC.
To: NEVAKAR INJECTABLES INC.
Reel/Frame 060607/0144 →
Cited By (1)
US 12,440,459